NCT01438125已完成2 期
A Pilot Study to Evaluate the Safety and Preliminary Efficacy of MF-4181 for the Reduction of Scars Secondary to Abdominoplasty or Laparoscopy/Laparotomy Gynecologic Procedures
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 3
- 主要终点
- Safety, defined as the absence of device related serious adverse events at 3 months post last MF-4181 treatment
研究概览
简要总结
The objective of the study is to evaluate the safety and preliminary efficacy of MF-4181, a hydrogel scaffold, in improving scars and their resulting consequences following abdominoplasty or laparoscopy/laparotomy gynecologic procedures.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects between 18 and 60 years of age undergoing abdominoplasty without intraoperative flexion at time of skin excision OR female subjects between 18 and 60 years of age undergoing diagnostic and/or operative laparoscopy/laparotomy gynecologic procedures.
- •Weight between 50 and 95 kg with BMI between 20 and 30
- •Able and willing to give written informed consent
- •Willing to comply with the follow-up schedule
排除标准
- •Need of concomitant surgical procedures that would be performed at the same time as the index surgical procedure or that would influence the healing process
- •Previous abdominal surgery with scars or adhesions that would limit or complicate the index surgical procedure
- •Presence of ventral or umbilical hernia requiring the use of prosthetic material
- •Heart disease
- •Pregnant or planning to become pregnant during the course of the study; the exception to this exclusion is if ectopic pregnancy is the reason for the procedure
- •History of coagulopathy or bleeding disorder
- •An American Society of Anesthesiologists (ASA) Score of >II
- •Known diabetes
- •Current or history of heavy smoking (i.e., 10 pack years)
- •Active skin disorder or other condition that may interfere with healing or history of such a condition
- •Planned use of an ON-Q® pain control device (I-Flow Corporation, Lake Forest, CA) or similar incisional intervention post index procedure
- •Active collagen vascular disease or vasculitis, e.g., systemic lupus erythematosus, polyarteritis, dermatomyositis, systemic scleroderma or thrombotic thrombocytopenic purpura
- •Anticipated use of DERMABOND® or another topical skin adhesive type of wound closure
- •Unwilling or unable to return for follow-up visits
- •Regular, continuous use of systemic corticosteroid therapy or topical corticosteroid use in the area to be treated
- •Current participation or participation within the last 3 months in the study of an investigational drug, device, or biologic
- •Unable or unwilling to follow post-operative instructions
- •Known hypersensitivity to MF-4181, dextran, or any of its constituent materials
- •Previous participation in this study to avoid multiple enrollments of an individual subject.
- •Chemotherapy or hormone therapy for cancer within the last 3 months, or probability that these treatments will be required during the 6 months of study participation.
- •Current or past radiation therapy in the abdominal incision
研究组 & 干预措施
MF-4181
Active Comparator
Scar halves randomized to treatment with device, opposite side treated per standard of care
干预措施: MF-4181 (Other)
Standard surgical wound closure
Active Comparator
干预措施: Standard surgical wound closure (Other)
结局指标
主要结局
Safety, defined as the absence of device related serious adverse events at 3 months post last MF-4181 treatment
时间窗: 3 Months
次要结局
- Investigator and Subject Observer Scar Assessment Scale (POSAS)(12 months)
- Investigator and Subject Anchored Visual Analog Scar Evaluation Scale(12 Months)
- Digital photographs evaluated by independent medical experts(12 Months)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Evaluation of the Initial Safety and Efficacy of Keloid Lesions Treated With MF-4181KeloidNCT01446770Halscion, Inc.19
Unknown
不适用
Intervertebral DXM Gel Injection in Adults With Painful Lumbar Degenerative Disc DiseaseChronic Lower Back PainDiscogenic PainIntervertebral Disc DegenerationLumbar Disc DiseaseLumbar Disc DegenerationLumbar Disc PainDegenerative Disc DiseaseNCT04727385Gelmetix20
进行中（未招募）
不适用
A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinoma, non resectableMedDRA version: 9.1Level: LLTClassification code 10033600Term: Pancreatic adenocarcinoma non-resectableEUCTR2006-005104-14-DEniversitätsklinikum Schleswig-Holstein20
已完成
1 期
Safety and Efficacy Study of Etanercept (Enbrel) on the Response Rate of HIV-infected SubjectsHIV InfectionNCT00091741Georgetown University10
招募中
1 期
BC008-1A Injection for Recurrent CNS WHO G4 GliomaGlioma Tumor RecurrenceGlioma, Recurrent High GradeGlioblastomas (GBM)Glioblastoma WHO Grade IVGliomaNCT06773481Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.40